Toward biologically targeted therapy of calcium cycling defects in heart failure

Physiology

Volumn 23, Issue 1, 2008, Pages 6-16

  Ikeda, Yasuhiro ^a   Hoshijima, Masahiko ^b   Chien, Kenneth R ^c  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE; PROTEIN KINASE (CALCIUM,CALMODULIN) II; RYANODINE RECEPTOR;

ANIMAL; CALCIUM SIGNALING; DISEASE COURSE; DRUG EFFECT; ENZYMOLOGY; GENE THERAPY; GENETICS; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; REVIEW; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM SIGNALING; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOTONIC AGENTS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE PROGRESSION; GENE THERAPY; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN PHOSPHATASE 1; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM;

EID: 40349088965     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00033.2007     Document Type: Review

References (118)

1. Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (C.U.P.I.D. Trial) (Online). http://www. celladon.net/press_may1707.php.
2. 2+ leak in heart failure. Circ Res 97: 1314-1322, 2005.
3. 2+-ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban. Proc Natl Acad Sci USA 100: 5040-5045, 2003.
4. Belin RJ, Sumandea MP, Allen EJ, Schoenfelt K, Wang H, Solaro RJ, de Tombe PP. Augmented protein kinase C-alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ Res 101: 195-204, 2007.
5. Berrebi-Bertrand I, Souchet M, Camelin JC, Laville MP, Calmels T, Bril A. Biophysical interaction between phospholamban and protein phosphatase 1 regulatory subunit GM. FEBS Lett 439: 224-230, 1998.
6. Bers DM. Cardiac excitation-contraction coupling. Nature 415: 198-205, 2002.
7. Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol 37: 417-429, 2004.
8. 2+ ATPase. J Mol Cell Cardiol 42: 903-911, 2007.
9. Bodi I, Mikala G, Koch SE, Akhter SA, Schwartz A. The L-type calcium channel in the heart: the beat goes on. J Clin Invest 115: 3306-3317, 2005.
10. Bohm M, Reiger B, Schwinger RH, Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 28: 1713-1719, 1994.
11. Bossuyt J, Ai X, Moorman JR, Pogwizd SM, Bers DM. Expression and phosphorylation of the napump regulatory subunit phospholemman in heart failure. Circ Res 97: 558-565, 2005.
12. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10: 248-254, 2004.
13. Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22: 4124-4135, 2002.
14. Carter S, Colyer J, Sitsapesan R. Maximum phosphorylation of the cardiac ryanodine receptor at serine-2809 by protein kinase a produces unique modifications to channel gating and conductance not observed at lower levels of phosphorylation. Circ Res 98: 1506-1513, 2006.
15. 2+ channels. Biophys J 79: 2547-2556, 2000.
16. 2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 91: 517-524, 2002.
17. 2+ overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res 97: 1009-1017, 2005.
18. i-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res 87: 1172-1179, 2000.
19. Chien KR. Beyond small molecule drugs for heart failure: prospects for gene therapy. Novartis Found Symp 274: 244-256; discussion 256-259, 272-276, 2006.
20. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. Nature 407: 227-232, 2000.
21. Chien KR. Stress pathways and heart failure. Cell 98: 555-558, 1999.
22. Chien KR, Ross J Jr, Hoshijima M. Calcium and heart failure: the cycle game. Nat Med 9: 508-509, 2003.
23. Curran J, Hinton MJ, Rios E, Bers DM, Shannon TR. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res 100: 391-398, 2007.
24. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396: 474-477, 1998.
25. Delling U, Sussman MA, Molkentin JD. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med 6: 942-943, 2000.
26. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, Liu W, Molina CA, Sadoshima J, Blaxall BC, Berk BC, Yan C. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 102: 14771-14776, 2005.
27. Dodge-Kafka KL, Langeberg L, Scott JD. Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. Circ Res 98: 993-1001, 2006.
28. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, Scott JD. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437: 574-578, 2005.
29. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, Langeberg LK, Scott JD. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 20: 1921-1930, 2001.
30. Drake MT, Shenoy SK, Lefkowitz RJ. Trafficking of G protein-coupled receptors. Circ Res 99: 570-582, 2006.
31. 2+/calmodulin-dependent protein kinase isoforms. Biochim Biophys Acta 1221: 89-101, 1994.
32. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 61: 87-93, 2004.
33. El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann WH, Jackel E, Harding SE, Boknik P, Neumann J, Eschenhagen T. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 17: 437-439, 2003.
34. Farrell EF, Antaramian A, Rueda A, Gomez AM, Valdivia HH. Sorcin inhibits calcium release and modulates excitation-contraction coupling in the heart. J Biol Chem 278: 34660-34666, 2003.
35. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, Vandecasteele G. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99: 816-828, 2006.
36. 2+/calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res 99: 398-406, 2006.
37. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285: H2373-H2381, 2003.
38. Gupta RC, Mishra S, Yang XP, Sabbah HN. Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol Cell Biochem 269: 49-57, 2005.
39. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW, 2nd MacLennan DH, Kremastinos DT, Kranias EG. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA 103: 1388-1393, 2006.
40. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW, 2nd MacLennan DH, Kremastinos DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111: 869-876, 2003.
41. Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, Kimball TF, Hewett TE, Dorn GW 2nd, Koch WJ, Molkentin JD. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 114: 574-582, 2006.
42. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34: 951-969, 2002.
43. 2+/calmodulin- dependent protein kinase in failing and nonfailing human myocardium. Circ Res 84: 713-721, 1999.
44. Hoshijima M. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol Ther 105: 211-228, 2005.
45. Hoshijima M, Chien KR. Mixed signals in heart failure: cancer rules. J Clin Invest 109: 849-855, 2002.
46. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y, Ross J Jr, Chien KR. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864-871, 2002.
47. Hoshijima M, Knoll R, Pashmforoush M, Chien KR. Reversal of calcium cycling defects in advanced heart failure toward molecular therapy. J Am Coll Cardiol 48: 15-23, 2006.
48. Huang B, Wang S, Qin D, Boutjdir M, El-Sherif N. Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases. Circ Res 85: 848-855, 1999.
49. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341: 1276-1283, 1999.
50. Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 113: 727-736, 2004.
51. Kaliman P, Catalucci D, Lam JT, Kondo R, Gutierrez JC, Reddy S, Palacin M, Zorzano A, Chien KR, Ruiz-Lozano P. Myotonic dystrophy protein kinase phosphorylates phospholamban and regulates calcium uptake in cardiomyocyte sarcoplasmic reticulum. J Biol Chem 280: 8016-8021, 2005.
52. Kapiloff MS. Contributions of protein kinase A anchoring proteins to compartmentation of cAMP signaling in the heart. Mol Pharmacol 62: 193-199, 2002.
53. Kaye DM, Preovolos A, Marshall T, Byrne M, Hoshijima M, Hajjar R, Mariani JA, Pepe S, Chien KR, Power JM. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 50: 253-260, 2007.
54. 2+-ATPase2a and phospholamban in the human heart. Biochem Biophys Res Commun 306: 550-557, 2003.
55. Kirchhefer U, Baba HA, Boknik P, Breeden KM, Mavila N, Bruchert N, Justus I, Matus M, Schmitz W, Depaoli-Roach AA, Neumann J. Enhanced cardiac function in mice overexpressing protein phosphatase inhibitor-2. Cardiovasc Res 68: 98-108, 2005.
56. 2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc Res 42: 254-261, 1999.
57. Kohlhaas M, Zhang T, Seidler T, Zibrova D, Dybkova N, Steen A, Wagner S, Chen L, Brown JH, Bers DM, Maier LS. Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res 98: 235-244, 2006.
58. Lai NC, Roth DM, Gao MH, Tang T, Dalton N, Lai YY, Spellman M, Clopton P, Hammond HK. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110: 330-336, 2004.
59. 2+-binding protein) and triadin in the lumen of sarcoplasmic reticulum. J Biol Chem 276: 39533-39538, 2001.
60. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123: 25-35, 2005.
61. Li Y, Kranias EG, Mignery GA, Bers DM. Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 90: 309-316, 2002.
62. Limas CJ, Olivari MT, Goldenberg IF, Levine TB, Benditt DG, Simon A. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 21: 601-605, 1987.
63. Luss H, Klein-Wiele O, Boknik P, Herzig S, Knapp J, Linck B, Muller FU, Scheld HH, Schmid C, Schmitz W, Neumann J. Regional expression of protein phosphatase type 1 and 2A catalytic subunit isoforms in the human heart. J Mol Cell Cardiol 32: 2349-2359, 2000.
64. MacDougall LK, Jones LR, Cohen P. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur J Biochem 196: 725-734, 1991.
65. 2+/calmodulin kinases in the heart: physiology and pathophysiology. Cardiovasc Res 73: 629-630, 2007.
66. Marx SO, Reiken S, Hisamatsu Y, Gaburjakova M, Gaburjakova J, Yang YM, Rosemblit N, Marks AR. Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine/isoleucine zippers. J Cell Biol 153: 699-708, 2001.
67. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376, 2000.
68. 2+-ATPase and modulates excitation-contraction coupling in the heart. Basic Res Cardiol 100: 250-262, 2005.
69. Metzger JM, Westfall MV. Covalent and noncovalent modification of thin filament action: the essential role of troponin in cardiac muscle regulation. Circ Res 94: 146-158, 2004.
70. Meyers MB, Pickel VM, Sheu SS, Sharma VK, Scotto KW, Fishman GI. Association of sorcin with the cardiac ryanodine receptor. J Biol Chem 270: 26411-26418, 1995.
71. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR. Chronic phospholamban- sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99: 313-322, 1999.
72. Minamisawa S, Wang Y, Chen J, Ishikawa Y, Chien KR, Matsuoka R. Atrial chamber-specific expression of sarcolipin is regulated during development and hypertrophic remodeling. J Biol Chem 278: 9570-9575, 2003.
73. 2+ uptake in human failing left ventricular myocardium. J Heart Lung Transplant 21: 366-373, 2002.
74. 2+- calmodulin-dependent protein kinase activity and expression in LV myocardium of dogs with heart failure. Am J Physiol Heart Circ Physiol 284: H876-H883, 2003.
75. 2+/calmodulin-dependent protein kinase is altered in heart failure. Circ Res 86: 596-605, 2000.
76. Nikolaev VO, Lohse MJ. Monitoring of cAMP synthesis and degradation in living cells. Physiology Bethesda 21: 86-92, 2006.
77. Noguchi T, Hunlich M, Camp PC, Begin KJ, El-Zaru M, Patten R, Leavitt BJ, Ittleman FP, Alpert NR, LeWinter MM, VanBuren P. Thin-filament-based modulation of contractile performance in human heart failure. Circulation 110: 982-987, 2004.
78. Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Marreez Y, Chen G, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96: 756-766, 2005.
79. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Weirich J, Posival H, Minami K, Just H, Hasenfuss G. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 92: 1169-1178, 1995.
80. Rodriguez P, Mitton B, Nicolaou P, Chen G, Kranias EG. Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol 293: H762-H769, 2007.
81. Rodriguez P, Mitton B, Waggoner JR, Kranias EG. Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem 281: 38599-38608, 2006.
82. Roth DM, Gao MH, Lai NC, Drumm J, Dalton N, Zhou JY, Zhu J, Entrikin D, Hammond HK. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99: 3099-3102, 1999.
83. Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E, Lunde PK, Christensen G. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 53: 382-391, 2002.
84. Sanoudou D, Vafiadaki E, Arvanitis DA, Kranias E, Kontrogianni- Konstantopoulos A. Array lessons from the heart: focus on the genome and transcriptome of cardiomyopathies. Physiol Genomics 21: 131-143, 2005.
85. Saucerman JJ, Zhang J, Martin JC, Peng LX, Stenbit AE, Tsien RY, McCulloch AD. Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes. Proc Natl Acad Sci USA 103: 12923-12928, 2006.
86. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410-1413, 2003.
87. 2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31: 479-491, 1999.
88. Sipido KR. CaM or cAMP: linking beta-adrenergic stimulation to 'leaky' RyRs. Circ Res 100: 296-298, 2007.
89. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111: 859-867, 2003.
90. Stange M, Xu L, Balshaw D, Yamaguchi N, Meissner G. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J Biol Chem 278: 51693-51702, 2003.
91. Steinberg SF, Brunton LL. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41: 751-773, 2001.
92. 2+/calmodulin-dependent protein kinases II in human atrial myocytes. Circ Res 85: 810-819, 1999.
93. 2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span. J Mol Cell Cardiol 41: 308-317, 2006.
94. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin SL, Conti M. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276: 11189-11198, 2001.
95. 2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest 116: 3127-3138, 2006.
96. Watanabe T, Huang HB, Horiuchi A, da Cruze Silva E.F, Hsieh-Wilson L, Allen PB, Shenolikar S, Greengard P, and Nairn AC. Protein phosphatase 1 regulation by inhibitors and targeting subunits. Proc Natl Acad Sci USA 98: 3080-3085, 2001.
97. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304: 292-296, 2004.
98. 2+/calmodulin- dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 94: e61-e70, 2004.
99. 2+ exchanger in failing pig myocytes. Circ Res 92: 897-903, 2003.
100. Wei SK, Ruknudin AM, Shou M, McCurley JM, Hanlon SU, Elgin E, Schulze DH, Haigney MC. Muscarinic modulation of the sodium-calcium exchanger in heart failure. Circulation 115: 1225-1233, 2007.
101. Westhoff JH, Hwang SY, Duncan RS, Ozawa F, Volpe P, Inokuchi K, Koulen P. Vesl/Homer proteins regulate ryanodine receptor type 2 function and intracellular calcium signaling. Cell Calcium 34: 261-269, 2003.
102. Wu Y, Colbran RJ, Anderson ME. Calmodulin kinase is a molecular switch for cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 98: 2877-2881, 2001.
103. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to Gs and Gi proteins. Sci STKE 2001: RE15, 2001.
104. Yamada M, Ikeda Y, Yano M, Yoshimura K, Nishino S, Aoyama H, Wang L, Aoki H, Matsuzaki M. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J 20: 1197-1199, 2006.
105. 2+/calmodulin-dependent protein kinase deltaC activate or inhibit the cardiac ryanodine receptor ion channel? Circ Res 100: 293-295, 2007.
106. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 100: 489-501, 2007.
107. 2+ waves in cardiac myocytes. Circ Res 100: 399-407, 2007.
108. 2+ handling in heart failure. J Clin Invest 115: 556-564, 2005.
109. Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, Okuda S, Suetsugu M, Hisaoka T, Obayashi M, Ohkusa T, Matsuzaki M. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107: 477-484, 2003.
110. 2+ leak through ryanodine receptor in heart failure. Circulation 102: 2131-2136, 2000.
111. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 100: 1569-1578, 2007.
112. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem 272: 23389-23397, 1997.
113. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11: 409-417, 2005.
114. 2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 63: 476-486, 2004.
115. 2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 277: 1261-1267, 2002.
116. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, Brown JH. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 92: 912-919, 2003.
117. 2+ homeostasis in the regulation of apoptotic and necrotic cell deaths. Cell Calcium 28: 107-117, 2000.
118. 2+/calmodulin kinase II. J Clin Invest 111: 617-625, 2003.